16. J Gynecol Obstet Hum Reprod. 2018 Jun 27. pii: S2468-7847(18)30167-3. doi:10.1016/j.jogoh.2018.06.007. [Epub ahead of print]Management and prognosis of pure primary squamous cell carcinoma of the breast.Benoist P(1), Mureau A(2), Joueidi Y(3), Arbion F(4), Vilde A(5), Body G(6),Michenet P(7), Leveque J(3), Ouldamer L(8).Author information: (1)Department of Gynecology, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2 boulevard Tonnellé, 37044 Tours, France; François-Rabelais University, Tours, France.(2)François-Rabelais University, Tours, France; Department of Radiology, CentreHospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2, boulevardTonnellé, 37044 Tours, France.(3)Department of Gynecology, Centre Hospitalier Régional Universitaire de Rennes,Anne de Bretagne, 16, boulevard de Bulgarie, 35203 Rennes, France; Department of Surgical Oncology, Eugene Marquis Comprehensive Cancer Center, avenue de labataille flandres dunkerque, 35042 Rennes, France.(4)Department of Pathology, Centre Hospitalier Régional Universitaire de Tours,Hôpital Bretonneau, 2, boulevard Tonnellé, 37044 Tours, France.(5)Department of Radiology, Centre Hospitalier Régional Universitaire de Tours,Hôpital Bretonneau, 2, boulevard Tonnellé, 37044 Tours, France.(6)Department of Gynecology, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2 boulevard Tonnellé, 37044 Tours, France; François-Rabelais University, Tours, France; INSERM unit 1069, Tours, France.(7)Department of Pathology, Centre Hospitalier Régional d'Orléans, Hôpital de la Source, 14, avenue de l'hôpital, 45067 Orléans, France.(8)Department of Gynecology, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2 boulevard Tonnellé, 37044 Tours, France; François-Rabelais University, Tours, France; INSERM unit 1069, Tours, France. Electronic address:l.ouldamer@chu-tours.fr.PURPOSE: The aim of the study was to investigate the management and prognosis of Pure primary squamous cell carcinoma (PPSCC) of the breast.MATERIALS AND METHODS: This study is a multicentre retrospective cohort fromthree French tertiary referral hospitals (Rennes, Orléans and Tours) includingall women treated for a PPSCC of the breast defined by squamous cells that could contain a minority of sarcomatoid component. We excluded carcinomas with aductual component. Clinicopathologic, radiological and therapeutic patterns were described. Demographic, histological and therapeutic characteristics werecompared to a population of women with triple negative invasive breastcarcinomas.RESULTS: Twelve patients were included, with a mean age of 71.6 years. Alllesions were unifocal, with a cystic complex ultrasound mass in 50% of cases.Mean tumor size was 43mm, with axillary lymph node metastasis in 25% of patients.The comparison with a population of women with triple negative breast carcinomas revealed that women with PPSCC were older (71 versus 57 years, p=0.003), tumorsize was larger (43mm versus 25mm, p=0.032) and local recurrence occurred earlier(three months versus 38 months, p=0.014).CONCLUSION: PPSCC is a rare entity with a worse prognosis in comparison withtriple negative invasive carcinoma.Copyright © 2018. Published by Elsevier Masson SAS.DOI: 10.1016/j.jogoh.2018.06.007 PMID: 29959086 